Department of Medicine 3 – Rheumatology and Immunology

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort (2019) Tascilar K, Aydin SZ, Akar S, Aksu K, Bakirci S, Bayindir O, Can M, et al. Conference contribution Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial (2019) Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial (2019) Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial (2019) Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, et al. Conference contribution The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019) Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al. Conference contribution Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS) (2019) Knitza J, Tascilar K, Messner EM, Meyer M, Vossen D, Pulla A, Bosch P, et al. Conference contribution Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort (2019) Costantino F, Aegerter P, Molto A, Schett G, Breban M, D'Agostino MA Conference contribution Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA (2019) De Moel E, Rech J, Mahler M, Roth J, Schouffoer A, Ronday K, Huizinga T, et al. Conference contribution